C-MER Medical (03309) has announced its interim results for the six months ended June 30, 2026, with group revenue reaching HK$1.024 billion, marking an 8.5% increase year-on-year. The company recorded a profit attributable to shareholders of HK$50.021 million, reflecting a modest 0.2% growth, with earnings per share standing at 4.21 HK cents.

The group delivers internationally benchmarked ophthalmology services under the "C-MER Eye" brand, addressing a wide spectrum of eye conditions ranging from common ailments to rare and complex diseases. In addition, the company operates Top Eye Centre Limited ("Top Eye"), a Hong Kong-based provider of ophthalmic services with over two decades of operational history, alongside Optometrist Eye Centre Limited, a vision care group offering myopia control, optometric assessments, and prescription eyewear and contact lens fitting services across Hong Kong.

As of June 30, 2026, the ophthalmology and related services network comprised five day-surgery centers, eight satellite clinics, and seven optometry centers. Since 2021, the company has expanded into dental, oncology, and other medical services in Hong Kong, which as of the reporting date included six dental clinics, one endoscopy center, and one oncology center.

In July 2022, the group initiated a clinical research business, potentially opening doors for collaborations with various biotechnology firms on research and clinical initiatives. During 2025, the company acquired an endoscopy center in Hong Kong to provide specialized procedures such as gastroscopy, colonoscopy, and cystoscopy.

By June 30, 2026, the company's mainland China ophthalmology network included nine eye hospitals located in Shenzhen (Futian and Bao'an), Beijing, Shanghai, Guangzhou, Zhuhai, Kunming, Huizhou, and Jieyang, primarily operating under the "C-MER Lin Shunchao" brand. Concurrently, the group has continued to refine its organizational structure and implement meticulous management practices in its operations. During the first half of 2026, the mainland China ophthalmology segment demonstrated sustained improvement, reporting a segment profit of HK$2.8 million compared to a break-even position in the corresponding period of 2025.